1018 related articles for article (PubMed ID: 32467995)
81. Off- and on-target effects of genome editing in mouse embryos.
Ayabe S; Nakashima K; Yoshiki A
J Reprod Dev; 2019 Feb; 65(1):1-5. PubMed ID: 30518723
[TBL] [Abstract][Full Text] [Related]
82. Strategies for the CRISPR-Based Therapeutics.
Li B; Niu Y; Ji W; Dong Y
Trends Pharmacol Sci; 2020 Jan; 41(1):55-65. PubMed ID: 31862124
[TBL] [Abstract][Full Text] [Related]
83. Recent advances in genome engineering by CRISPR technology.
Lee Y; Oh Y; Lee SH
BMB Rep; 2024 Jan; 57(1):12-18. PubMed ID: 38053294
[TBL] [Abstract][Full Text] [Related]
84. Application of CRISPR/Cas9 in Crop Quality Improvement.
Liu Q; Yang F; Zhang J; Liu H; Rahman S; Islam S; Ma W; She M
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921600
[TBL] [Abstract][Full Text] [Related]
85. CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia.
Chadwick AC; Musunuru K
Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):12-18. PubMed ID: 28838920
[TBL] [Abstract][Full Text] [Related]
86. CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges.
Cheng X; Fan S; Wen C; Du X
Brief Funct Genomics; 2020 May; 19(3):209-214. PubMed ID: 32052006
[TBL] [Abstract][Full Text] [Related]
87. Diversification of the CRISPR Toolbox: Applications of CRISPR-Cas Systems Beyond Genome Editing.
Balderston S; Clouse G; Ripoll JJ; Pratt GK; Gasiunas G; Bock JO; Bennett EP; Aran K
CRISPR J; 2021 Jun; 4(3):400-415. PubMed ID: 34152221
[TBL] [Abstract][Full Text] [Related]
88. Era of Genomic Medicine: A Narrative Review on CRISPR Technology as a Potential Therapeutic Tool for Human Diseases.
Kotagama OW; Jayasinghe CD; Abeysinghe T
Biomed Res Int; 2019; 2019():1369682. PubMed ID: 31687377
[TBL] [Abstract][Full Text] [Related]
89. Rapid Screening of CRISPR/Cas9-Induced Mutants Using the ACT-PCR Method.
Wang C; Wang K
Methods Mol Biol; 2019; 1917():27-32. PubMed ID: 30610625
[TBL] [Abstract][Full Text] [Related]
90. CRISPR-Cas Tools and Their Application in Genetic Engineering of Human Stem Cells and Organoids.
Hendriks D; Clevers H; Artegiani B
Cell Stem Cell; 2020 Nov; 27(5):705-731. PubMed ID: 33157047
[TBL] [Abstract][Full Text] [Related]
91. Nuclease-Deficient Clustered Regularly Interspaced Short Palindromic Repeat-Based Approaches for
Lek A; Ma K; Woodman KG; Lek M
Hum Gene Ther; 2021 Mar; 32(5-6):260-274. PubMed ID: 33446040
[TBL] [Abstract][Full Text] [Related]
92. [CRISPR/Cas-based genome editing in Aspergillus niger].
Zheng X; Zheng P; Sun J
Sheng Wu Gong Cheng Xue Bao; 2021 Mar; 37(3):980-990. PubMed ID: 33783162
[TBL] [Abstract][Full Text] [Related]
93. One-step generation of conditional and reversible gene knockouts.
Andersson-Rolf A; Mustata RC; Merenda A; Kim J; Perera S; Grego T; Andrews K; Tremble K; Silva JC; Fink J; Skarnes WC; Koo BK
Nat Methods; 2017 Mar; 14(3):287-289. PubMed ID: 28135257
[TBL] [Abstract][Full Text] [Related]
94. Editing
Dehshahri A; Biagioni A; Bayat H; Lee EHC; Hashemabadi M; Fekri HS; Zarrabi A; Mohammadinejad R; Kumar AP
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768751
[TBL] [Abstract][Full Text] [Related]
95. Recent Advances in CRISPR/Cas9 Delivery Approaches for Therapeutic Gene Editing of Stem Cells.
Lotfi M; Morshedi Rad D; Mashhadi SS; Ashouri A; Mojarrad M; Mozaffari-Jovin S; Farrokhi S; Hashemi M; Lotfi M; Ebrahimi Warkiani M; Abbaszadegan MR
Stem Cell Rev Rep; 2023 Nov; 19(8):2576-2596. PubMed ID: 37723364
[TBL] [Abstract][Full Text] [Related]
96. CRISPR/Cas9-based genome editing for simultaneous interference with gene expression and protein stability.
Martínez V; Lauritsen I; Hobel T; Li S; Nielsen AT; Nørholm MHH
Nucleic Acids Res; 2017 Nov; 45(20):e171. PubMed ID: 28981713
[TBL] [Abstract][Full Text] [Related]
97. CRISPR off-targets: a question of context.
Haeussler M
Cell Biol Toxicol; 2020 Feb; 36(1):5-9. PubMed ID: 31734746
[No Abstract] [Full Text] [Related]
98. CRISPR/Cas9 Genome Editing Approaches for Psychiatric Research.
Gutiérrez-Rodríguez A; Cruz-Fuentes CS; Genis-Mendoza AD; Nicolini H
Braz J Psychiatry; 2023 May; 45(2):137-145. PubMed ID: 36753615
[TBL] [Abstract][Full Text] [Related]
99. Therapeutic and diagnostic relevance of Crispr technology.
El Ouar I; Djekoun A
Biomed Pharmacother; 2021 Jun; 138():111487. PubMed ID: 33774312
[TBL] [Abstract][Full Text] [Related]
100. Human induced pluripotent stem cells and CRISPR/Cas-mediated targeted genome editing: Platforms to tackle sensorineural hearing loss.
Stojkovic M; Han D; Jeong M; Stojkovic P; Stankovic KM
Stem Cells; 2021 Jun; 39(6):673-696. PubMed ID: 33586253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
